Mechanisms of T cell-mediated hypertension in females and males
女性和男性 T 细胞介导的高血压机制
基本信息
- 批准号:9028818
- 负责人:
- 金额:$ 38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-01-01 至 2019-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAdultAffectAgeAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAortaArteriesAttenuatedAutomobile DrivingBiological AvailabilityBlood PressureBlood VesselsCardiovascular DiseasesCellsCessation of lifeChronicChronic Kidney FailureDataDevelopmentEndothelial CellsEnvironmentEquilibriumExhibitsFemaleFigs - dietaryFoundationsGoalsHeart failureHypertensionHypotensionImmuneIn VitroInbred SHR RatsInterleukin-10KidneyKidney TransplantationKnowledgeLeftLiteratureMaintenanceMeasuresMediatingMesenteric ArteriesMissionMolecularMorbidity - disease rateMyocardial InfarctionNatriuresisNitric OxideNitric Oxide SynthasePatientsPeripheral arterial diseasePharmaceutical PreparationsProductionProteinuriaPublishingRegulatory T-LymphocyteRenal functionReportingRiskRisk FactorsRoleSeveritiesSex CharacteristicsStrokeT-Cell ActivationT-Cell DepletionT-LymphocyteTestingUnited States National Institutes of HealthVasodilationWomanage relatedattenuationblood pressure reductionblood pressure regulationcardiovascular risk factorcytokineimprovedinhibitor/antagonistinterleukin-10 receptorkidney vascular structuremalemenmortalitynovelpre-clinicalprematurepressurepreventpublic health relevancereceptor expressionresponsesextargeted treatmentyoung woman
项目摘要
DESCRIPTION (provided by applicant): Hypertension affects ~33% of adults in the U.S. and is a risk factor for cardiovascular disease. Fewer than 40% of hypertensive patients control their blood pressure (BP) with current medication, leaving 60% at heightened risk for cardiovascular morbidity and mortality. Although both sexes develop hypertension, young women are protected from hypertension relative to age-matched men. The identification of mechanisms by which females delay increases in BP is an underutilized approach that can be exploited to develop improved treatment options for both sexes. A critical barrier to improving BP control rates is the lack of knowledge regarding the molecular mechanisms driving elevated BP in either sex. Our goal is to address these gaps by advancing our understanding of the role of T cells in BP control in males and females. There is growing support for a causal role for effector T cells in hypertension in male animal models. Data in females are largely lacking, however, we reported that female spontaneously hypertensive rats (SHR) have more regulatory T cells (Tregs) than males. Tregs limit increases in BP in males and our preliminary data shows that Treg expansion decreases BP in female SHR. Our central hypothesis is that although effector T cells cause hypertension in both sexes, greater Tregs in females mitigate T cell-mediated hypertension via increased interleukin (IL)-10 induced nitric oxide (NO) production. Treg-mediated attenuation hypertension in male animals is associated with increased NO-dependent vasodilation, and preliminary data indicates NOS activity increases concomitant with increases in Tregs only in female SHR. Two Specific Aims will test our hypothesis. Aim 1 will test the hypothesis that greater Tregs in females limit increases in BP relative to males. We will determine the impact of sex on renal and vascular T cell activation and function and measure BP responses, proteinuria, and vascular function following total T cell depletion and Treg depletion/expansion. Adoptive transfer studies will determine if T cells from males vs. females have innate differences impacting differentiation, or if the local environment is more critical in defining the immune profile. Renal transplant studies will determine of the role of the kidney vs. circulating factors n defining T cell profiles. Aim 2 will test the hypothesis that females have greater Treg-mediated increase in NO bioavailability via IL-10 resulting in improved vascular endothelial and renal function. We will measure NO bioavailability following Treg depletion/expansion in the absence and presence of IL-10 blockers. We will measure the contribution of Treg and IL-10-mediated NO release on the pressure natriuresis curve and vascular function. We will assess the contribution of Treg-mediated NO production on BP control during chronic NOS inhibition. Results will provide necessary pre-clinical foundation to support the development of novel, more refined approaches to target specific immune components in a sex- specific manner to improve BP control rates. Therapies targeting the pathophysiological cause of hypertension will undoubtedly improve BP control rates and prevent premature death from cardiovascular disease.
描述(申请人提供):高血压影响约33%的美国成年人,是心血管疾病的危险因素。只有不到40%的高血压患者用目前的药物控制他们的血压,60%的患者面临心血管疾病发病率和死亡率的高风险。尽管男女都会患上高血压,但年轻女性比年龄匹配的男性更容易患上高血压。确定女性延缓血压升高的机制是一种未得到充分利用的方法,可以用来为两性开发更好的治疗方案。提高血压控制率的一个关键障碍是缺乏关于推动两性血压升高的分子机制的知识。我们的目标是通过促进我们对T细胞在男性和女性血压控制中的作用的理解来解决这些差距。越来越多的人支持效应T细胞在雄性动物模型高血压中的因果作用。然而,我们报道了雌性自发性高血压大鼠(SHR)比雄性自发性高血压大鼠(SHR)拥有更多的调节性T细胞(Treg)。Treg限制了男性的血压升高,我们的初步数据显示,Treg的扩张降低了女性SHR的血压。我们的中心假设是,尽管效应性T细胞在两性中都会引起高血压,但女性体内更大的Treg通过增加白细胞介素10(IL-10)诱导的一氧化氮(NO)的产生来缓解T细胞介导的高血压。雄性动物的Treg介导的衰减性高血压与NO依赖的血管扩张增加有关,初步数据表明,只有雌性SHR的NOS活性增加伴随Tregs的增加。两个具体目标将检验我们的假设。目标1将检验这样一种假设,即女性的大三叉神经节限制了相对于男性的血压增加。我们将确定性别对肾脏和血管T细胞激活和功能的影响,并测量T细胞全耗尽和Treg耗尽/扩增后的血压反应、蛋白尿和血管功能。过继转移研究将确定来自男性和女性的T细胞是否存在影响分化的先天差异,或者当地环境在定义免疫特征方面是否更关键。肾移植研究将确定肾脏与决定T细胞类型的循环因素之间的作用。目的2将验证这一假设,即女性有更大的Treg介导的NO生物利用度通过IL-10增加,从而改善血管内皮细胞和肾功能。我们将在缺乏和存在IL-10阻滞剂的情况下,测量Treg耗尽/扩张后的生物利用度。我们将测量Treg和IL-10介导的NO释放对压力钠尿曲线和血管功能的贡献。我们将评估慢性一氧化氮合酶抑制期间Treg介导的NO产生对血压控制的贡献。结果将提供必要的临床前基础,以支持开发新的、更精细的方法,以性别特定的方式针对特定的免疫成分,以提高BP控制率。针对高血压的病理生理原因的治疗无疑将提高血压控制率,防止心血管疾病导致的过早死亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer C Sullivan其他文献
Jennifer C Sullivan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennifer C Sullivan', 18)}}的其他基金
Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk) - Leadership Administrative Core (LAC)
提高女性高血压患者的意识:ROAR(农村、肥胖、危险)- 领导行政核心 (LAC)
- 批准号:
10714534 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Mechanisms of subclinical renal injury in females following AKI: implications for adverse pregnancy outcomes
AKI 后女性亚临床肾损伤的机制:对不良妊娠结局的影响
- 批准号:
10568101 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk)
提高女性高血压患者的意识:ROAR(农村、肥胖、危险)
- 批准号:
10714530 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Mechanisms Driving Enhanced Susceptibility of Females versus Males to High-Fat Diet-Induced Increases in High Blood Pressure
女性与男性相比,对高脂肪饮食引起的高血压的易感性增强的机制
- 批准号:
10714531 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Sex Differences in Hypertension: Contribution of DAMPs
高血压的性别差异:DAMP 的贡献
- 批准号:
10094231 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
Mechanisms of T Cell-Mediated Hypertension In Females and Males
女性和男性 T 细胞介导的高血压机制
- 批准号:
9198049 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Sexual dimorphisms of renin-angiotensin system in hypertension and renal injury
高血压和肾损伤中肾素-血管紧张素系统的性别二态性
- 批准号:
8307938 - 财政年份:2009
- 资助金额:
$ 38万 - 项目类别:
Role of the renin-angiotensin system in sexual dimorphisms in the development of
肾素-血管紧张素系统在性二态性发育中的作用
- 批准号:
7851391 - 财政年份:2009
- 资助金额:
$ 38万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 38万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 38万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 38万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 38万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 38万 - 项目类别:














{{item.name}}会员




